Director at Cytokinetics (NASDAQ: CYTK) awarded shares and options
Rhea-AI Filing Summary
Cytokinetics director B. Lynne Parshall received new equity awards. On 2026-05-27, she was granted 2,851 shares of Cytokinetics common stock at no cost, increasing her direct holdings to 20,784 shares.
She was also granted a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share, expiring on 2036-05-26. These awards are compensation-related grants rather than open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,851 shares
Net Buy
2 txns
Insider
PARSHALL B LYNNE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 2,851 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 4,301 shares (Direct);
Common Stock — 20,784 shares (Direct)
Key Figures
Common stock grant: 2,851 shares
Shares held after grant: 20,784 shares
Option grant size: 4,301 shares
+2 more
5 metrics
Common stock grant
2,851 shares
Awarded on 2026-05-27 at $0.00 per share
Shares held after grant
20,784 shares
Director’s direct common stock holdings post-transaction
Option grant size
4,301 shares
Non-qualified stock option covering common stock
Option exercise price
$77.15 per share
Conversion or exercise price for the option
Option expiration
2036-05-26
Expiration date of the non-qualified stock option
Key Terms
Non-Qualified Stock Option (Right to Buy), grant/award acquisition, Form 4, exercise price
4 terms
Non-Qualified Stock Option (Right to Buy) financial
"security_title: "Non-Qualified Stock Option (Right to Buy)""
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
exercise price financial
"conversion_or_exercise_price: "77.1500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did CYTK director B. Lynne Parshall report in this Form 4?
Director B. Lynne Parshall reported receiving equity awards in Cytokinetics common stock. She was granted 2,851 shares at no cost and a non-qualified stock option for 4,301 shares, reflecting compensation rather than open-market trading activity.
What are the key terms of the stock options granted to the CYTK director?
The director received a non-qualified stock option covering 4,301 shares of Cytokinetics common stock. The option has an exercise price of $77.15 per share and an expiration date of 2036-05-26, providing long-term potential equity exposure.
Is the CYTK director’s option grant linked to any remaining derivative holdings?
This filing shows a newly granted non-qualified stock option for 4,301 shares as of 2026-05-27. The derivative summary does not list additional remaining derivative positions beyond this award in the provided data.